Isocitrate Dehydrogenase (IDH) Inhibitors Market Report 2026

Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview

• Isocitrate Dehydrogenase (IDH) Inhibitors market size has reached to $2.46 billion in 2025 • Expected to grow to $8.02 billion in 2030 at a compound annual growth rate (CAGR) of 26.6% • Growth Driver: Increase In Acute Myeloid Leukemia Driving Growth Of The Market Due To Rising Incidence Among Aging And At-Risk Populations • Market Trend: FDA Approves First Targeted Therapy For Grade 2 IDH-Mutant Glioma • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Isocitrate Dehydrogenase (IDH) Inhibitors Market?

Isocitrate Dehydrogenase (IDH) Inhibitors are a class of targeted cancer therapies designed to block the activity of mutated forms of the IDH1 and IDH2 enzymes. These enzymes are involved in cellular metabolism, and gene mutations can lead to abnormal cell growth and cancer development. The main types of isocitrate dehydrogenase (IDH) inhibitors are IDH1 mutant medullary malignant tumor, IDH2 mutant medullary malignant tumor, and others. IDH1 mutant medullary malignant tumor refers to a type of cancerous growth that originates in the medullary (central) part of an organ or tissue and is characterized by a mutation in the IDH1 gene. It includes molecule types, such as monoclonal antibodies, peptides, small molecules, and others, and is administered through oral, parenteral, subcutaneous, and topical routes. It is used for applications such as FLT3 inhibitors, DH inhibitors, hedgehog pathway inhibitors, and others.

What Is The Isocitrate Dehydrogenase (IDH) Inhibitors Market Growth Forecast?

The isocitrate dehydrogenase (idh) inhibitors market size is expected to see exponential growth in the next few years. It will grow to $8.02 billion in 2030 at a compound annual growth rate (CAGR) of 26.6%. The growth in the forecast period can be attributed to precision medicine advancement, biomarker-driven oncology care, rare cancer drug pipelines, combination cancer therapies, regulatory support for targeted drugs. Major trends in the forecast period include expansion of targeted oncology therapies, increased genetic mutation-based drug development, growing focus on rare cancer treatment, rising use of precision oncology diagnostics, advancement of small molecule cancer inhibitors.

Global Isocitrate Dehydrogenase (IDH) Inhibitors Market Segmentation

1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types 2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types 3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical 4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications Subsegments: 1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma 2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL) 3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers

What Is The Driver Of The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

The increase in the frequency of acute myeloid leukemia is expected to propel the growth of the isocitrate dehydrogenase (IDH) inhibitors market going forward. Acute myeloid leukemia (AML) refers to a fast-growing cancer of the blood and bone marrow characterized by the rapid production of abnormal white blood cells that interfere with normal blood cell formation. The increase in the incidence of acute myeloid leukemia is due to the rise in the aging population as older adults face a higher risk of developing this aggressive blood cancer due to age-related changes in their bone marrow and immune system. Isocitrate dehydrogenase (IDH) inhibitors help treat acute myeloid leukemia by blocking mutant IDH enzymes, which restores normal blood cell development and slow the growth of leukemia cells. For instance, in February 2023, according to the report published by Leukaemia Foundation, an Australia-based non-profit organization, from 2022 to 2035, more than 7,000 children, 6,000 young adults, and 108,000 adults aged 25–65 are expected to be diagnosed with blood cancers, primarily acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Therefore, an increase in the frequency of acute myeloid leukemia is expected to propel the growth of the isocitrate dehydrogenase (IDH) inhibitors industry.

Key Players In The Global Isocitrate Dehydrogenase (IDH) Inhibitors Market

Major companies operating in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology Inc., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC

Global Isocitrate Dehydrogenase (IDH) Inhibitors Market Trends and Insights

Major companies operating in the isocitrate dehydrogenase (IDH) inhibitors market are focusing on obtaining regulatory approvals to expand the clinical use of their therapies, accelerate market entry, and gain a competitive advantage in treating IDH-mutant cancers. Regulatory approvals refer to official permissions granted by health authorities that allow a drug to be marketed and used after confirming its safety and effectiveness. For instance, in August 2024, Servier Laboratoires, a France-based pharmaceutical company, received FDA approval for VORANIGO (vorasidenib) tablets as the first targeted therapy for patients with Grade 2 IDH-mutant glioma, including astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. This oral treatment significantly improves progression-free survival, as shown in the Phase 3 INDIGO trial, where patients had a median progression-free survival of 27.7 months versus 11.1 months for placebo. VORANIGO offers a convenient and well-tolerated option with manageable side effects, marking a significant advancement for a patient group with limited prior treatment choices.

What Are Latest Mergers And Acquisitions In The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

In November 2025, Amoy Diagnostics Co. Ltd., a China-based healthcare technology company, partnered with Servier, to expand precision oncology and genetic testing solutions. With this partnership, Amoy Diagnostics and Servier aim to enhance cancer and rare disease diagnostics by combining Amoy’s molecular diagnostic assays with Servier’s clinical genomics and therapeutic expertise to provide faster, more accurate, and widely accessible testing, while improving data interpretation, streamlining laboratory workflows, and enabling broader patient access to personalized medicine. Servier is a France-based healthcare technology company that specializes in developing and commercializing innovative therapeutics and diagnostic solutions across oncology, cardiology, and rare diseases.

Regional Insights

North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Isocitrate Dehydrogenase (IDH) Inhibitors Market?

The isocitrate dehydrogenase (IDH) inhibitors market consists of sales of selective IDH1 inhibitors, selective IDH2 inhibitors, dual IDH1/IDH2 inhibitors, combination therapies, and delivery forms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods, such as formulation development, packaging, and regulatory support.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Isocitrate Dehydrogenase (IDH) Inhibitors Market Report 2026?

The isocitrate dehydrogenase (idh) inhibitors market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the isocitrate dehydrogenase (idh) inhibitors industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.